Featured image: Microscopy illustrates laboratory research. Contextual photograph; not the EPCORE DLBCL-2 trial or one of its participants. Photo: Lucas Vasques / Unsplash. Unsplash licence.
An antibody that brings immune cells close to cancer cells has produced a significant result in a large trial of newly diagnosed lymphoma. The development moves a therapeutic platform into a different part of the cancer-treatment debate: its use at the beginning of treatment.
On 5 October 2026, Genmab and AbbVie announced positive topline results from EPCORE DLBCL-2, a Phase III trial of epcoritamab with R-CHOP chemotherapy. The companies reported a 51% reduction in the risk of disease progression or death compared with R-CHOP alone. These are company-reported results; the combination remains investigational. Read the trial announcement.
Two binding sites connect different cells
A bispecific antibody has two different binding targets. Epcoritamab binds CD3 on T cells, which participate in immune defence, and CD20 on B cells. Its design brings a T cell into contact with a CD20-bearing cell so that the immune cell can attack it. The FDA’s earlier description of the antibody.
DLBCL stands for diffuse large B-cell lymphoma. The trial tests an addition to an established multi-drug regimen, rather than replacement of chemotherapy with an antibody alone. R-CHOP combines rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone. The registered trial protocol.
That distinction matters when describing the platform. A positive combination result tells us about the combined regimen in the studied setting. It cannot show that the antibody, used on its own, would produce the same outcome.
The 51% figure describes a relative hazard
The primary analysis involved patients with International Prognostic Index scores of 3–5. This index groups several clinical features used to assess prognosis. The reported hazard ratio was 0.49, with a 95% confidence interval of 0.35–0.69. The wider group with scores of 2–5 also had a reported hazard ratio of 0.49. Primary and wider-population results.
A hazard ratio compares the rate of an event over follow-up. The result does not mean that 51 additional people out of every 100 were cured. Nor does it provide the absolute difference in outcomes at a particular time without the underlying survival data.
Progression-free survival counts time until the cancer progresses or the participant dies. Overall survival measures time until death from any cause. The registry lists both outcomes, with progression-free survival as the primary measure. One endpoint should not silently stand in for the other.
For a public reader, the most useful next numbers will include the proportions remaining progression-free at stated times, length of follow-up and the overall-survival analysis. Those would make the relative result easier to assess in practical terms.
Existing approvals provide context for a new combination
Epcoritamab already has approvals in other lymphoma settings. For example, the FDA’s 18 November 2025 announcement covered specific relapsed or refractory follicular lymphoma uses. That is a different disease setting and regimen from newly diagnosed DLBCL with R-CHOP.
The FDA notice also records boxed warnings for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. These involve excessive immune activation and neurological complications respectively. The warning provides relevant background; it does not establish their frequency in the new trial.
A full assessment needs the new combination’s adverse-event tables, infections, treatment discontinuations and recovery information alongside its cancer-control results. Describing tolerability without those details would leave an important part of the comparison unresolved.
The next evidence must fill out the headline
The companies say they will submit the data for a medical meeting and engage regulators. Their announcement does not report an approval for this combination.
Our assessment is that the significant advance is a randomized Phase III signal for bringing a T-cell-engaging antibody into initial treatment. The remaining task is to establish the size, durability and burdens of the benefit in the full dataset. A strong headline result makes that scrutiny more valuable, rather than making it unnecessary.
Leave a Reply